{
    "nct_id": "NCT05878184",
    "official_title": "A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)",
    "inclusion_criteria": "* Male or female subjects aged 18-80 years at the time of signing informed consent.\n* Diagnosis of NHL (WHO 2016 criteria) or CLL (iwCLL criteria), including:\n* Large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise - - specified (including DLBCL arising from indolent lymphoma), primary mediastinal large -- - B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma grade 3B\n* Follicular lymphoma (dose escalation only except for follicular lymphoma grade 3B)\n* Marginal zone lymphoma (dose escalation only)\n* Mantle cell lymphoma (dose escalation only)\n* CLL or SLL\n* Relapsed/refractory disease after at least 2 prior systemic regimens per standard of care or after autologous stem cell transplant\n* ECOG performance status of 0 or 1.\n* At least one measurable lesion per Lugano Classification (NHL); CLL subjects must meet iwCLL treatment criteria\n* Life expectancy â‰¥12 weeks\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Prior anti-CD19 therapy including CD19-directed CAR T treatment or other CD19-directed antibody or cell therapy (e.g., NK cell). (Part 2 dose expansion only - prior approved CD19-directed CAR T therapy required)\n* History of primary central nervous system (CNS) lymphoma or presence of CNS metastases\n* Systemic anticancer therapy (including platinum-based chemotherapies and I/O therapies) or radiotherapy within 14 days of SC291 (28 days for biologics)\n* Autologous HSCT within 6 weeks of treatment with SC291 (or allogeneic HSCT at any time).\n* Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as >20 mg/day prednisone or equivalent).\n* History or presence of cardiac or CNS disorders as defined in the protocol",
    "miscellaneous_criteria": ""
}